News

We will be exhibiting at EASL’s ILC 10th-14th April in Vienna. Come meet our colleagues Reda Elkhatib, Paola Pellegrini and Jessica Tuohy at our booth at the Biotech Village. Herzlich willkommen!

The International Liver Congress will take place in Vienna this year, and VLVbio will be exhibiting. Come meet us there!

The Internation Liver Congress (ILC) is the flagship event of the year for all of us with a huge interest in hepatology. Every year in April, scientific and medical experts from a broad range of fields, including among others hepatology, infectuous diseases and transplantation, come together from around the world to learn about the latest within the liver field.

Researchers share their recent data, present studies and findings, and discuss the hottest topics on liver disease. The congress attracts around 10 000 people from all over the world!

We will be attending the ILC in Vienna 10th-14th April 2019, where we will exhibit at the Biotech Village. Come join us there!

The Use of Cytokeratin 18 Assays as a Prescreening Tool

Read the blog post on how to use the Keratin 18 assays in NASH clinical trials!

Non‐alcoholic fatty liver disease (NAFLD) is a growing global epidemic and the most common cause of liver disease in all Western countries. NAFLD refers to a spectrum of conditions and it is defined as the excessive accumulation of fat in the liver not caused by heavy alcohol consumption.

Patients with non-alcoholic steatohepatitis (NASH), a more advanced form of NAFLD, are at an increased risk for liver-related mortality and cardiovascular disease. There are currently no approved drug therapies for NAFLD or NASH and many clinical trials are underway to address this unmet need for pharmacologic treatment options.

Read about the challenges faced by pharmaceutical companies involved in NASH clinical trials and how the K18 assays can result in both time and cost savings, and show efficacy of NASH drug treatment.

Read the post here!

M30 Apoptosense in NASH Clinical Trials

We are proud to announce that the M30 Apoptosense® ELISA, for use in NASH clinical trials, will be discussed on an Xtalks webinar!

NAFLD is a medical condition characterized by the build-up of fat in the liver and has a spectrum that ranges from steatosis and NASH to fibrotic NASH and cirrhosis. The incidence of NAFLD worldwide is 20-35%, and there are currently no approved drug therapies for NAFLD or NASH.

As biopsy is still the “gold standard” for diagnosis of NASH, non-invasive biomarkers are urgently needed to identify patients and determine their response to novel therapeutic agents.

Markers of hepatic cell death such as keratin 18 (K18) and its caspase-cleaved fragment, ccK18, have been suggested as endpoints for early clinical drug trials. The M30 Apoptosense® ELISA is a specific and reliable tool to measure the concentration of ccK18 fragments. Celerion has validated the M30 Apoptosense® ELISA for use as a secondary endpoint in NASH clinical trials.

Webinar Information

• Monday, October 22, 2018
• 11am EDT (NA)
• 4pm BST (UK)
• 5pm CEST (EU-Central)
• Duration: 60 min

This webinar is sponsored by Diapharma Group, Inc

Click here to register and listen to the free webinar!

EASL – NAFLD SUMMIT 2018

VLVbio will exhibit at the EASL event NAFLD SUMMIT 2018 in Geneve, Switzerland the 20th to 22nd of September.
Meet us there and let us discuss biomarkers!

We will exhibit at The International Liver Congress 2018 in Paris, France.

VLVbio will attend and exhibit at The International Liver Congress in Paris, between the 11th and the 15th of April.

Meet our team members in the exhibition area, and learn about our Keratin 18 biomarker assays.

We will attend the NAFLD Summit EASL event in Rome, Italy November 9-11. Meet our team members from VLVbio and Diapharma Group, Inc. Giannella Coghlan, Adrian Kling and Jessica Tuohy at VLVbio’s space in the exhibition area. Ti vediamo!

We will attend the NAFLD Summit EASL event in Rome, Italy November 9-11.